Literature DB >> 24682137

Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists.

Tanaka Ngcozana1, Voon Ong, Christopher Paul Denton.   

Abstract

Two patients with scleroderma and recurrent digital ulcers (DUs) were treated with bosentan for 6 months. Treatment was associated with a reduction in the number of new DUs; however, DUs recurred on treatment discontinuation. This case report illustrates the positive response of digital vasculopathy to bosentan and describes the benefits of multiple bosentan treatment courses in these patients.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24682137      PMCID： PMC3975530          DOI： 10.1136/bcr-2013-203174

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  15 in total

1.  Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.

Authors:  José Andrés Roman Ivorra; Carmen Pilar Simeon; Juan José Alegre Sancho; Maria Victoria Egurbide; Maria Jesús Castillo; Xavier Lloria; Vicent Fonollosa
Journal:  J Rheumatol       Date:  2011-06-01       Impact factor: 4.666

2.  Bosentan fosters microvascular de-remodelling in systemic sclerosis.

Authors:  S Guiducci; S Bellando Randone; C Bruni; G Carnesecchi; A Maresta; F Iannone; G Lapadula; M Matucci Cerinic
Journal:  Clin Rheumatol       Date:  2012-09-29       Impact factor: 2.980

3.  A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact.

Authors:  H Ennis; A Vail; E Wragg; A Taylor; T Moore; A Murray; L Muir; C E M Griffiths; A L Herrick
Journal:  Scand J Rheumatol       Date:  2013-07-04       Impact factor: 3.641

4.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.

Authors:  U A Walker; A Tyndall; L Czirják; C Denton; D Farge-Bancel; O Kowal-Bielecka; U Müller-Ladner; C Bocelli-Tyndall; M Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2007-01-18       Impact factor: 19.103

5.  Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study.

Authors:  Eric Hachulla; Pierre Clerson; David Launay; Marc Lambert; Sandrine Morell-Dubois; Viviane Queyrel; Pierre-Yves Hatron
Journal:  J Rheumatol       Date:  2007-11-01       Impact factor: 4.666

6.  Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.

Authors:  F Cozzi; E Pigatto; M Rizzo; M Favaro; E Zanatta; S Cardarelli; L Riato; L Punzi
Journal:  Clin Rheumatol       Date:  2013-01-24       Impact factor: 2.980

7.  Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis.

Authors:  L Mouthon; C Mestre-Stanislas; A Bérezné; F Rannou; P Guilpain; M Revel; C Pagnoux; L Guillevin; J Fermanian; S Poiraudeau
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

8.  Effects of bosentan on the skin lesions: an observational study from a single center in Japan.

Authors:  Masanori Funauchi; K Kishimoto; H Shimazu; Y Nagare; S Hino; T Yano; K Kinoshita
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

9.  Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.

Authors:  P García de la Peña-Lefebvre; S Rodríguez Rubio; M Valero Expósito; L Carmona; M L Gámir Gámir; J Beltrán Gutiérrez; C Díaz-Miguel; J Orte Martínez; A C Zea Mendoza
Journal:  Rheumatology (Oxford)       Date:  2008-02-07       Impact factor: 7.580

10.  Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.

Authors:  Marco Matucci-Cerinic; Christopher P Denton; Daniel E Furst; Maureen D Mayes; Vivien M Hsu; Patrick Carpentier; Fredrick M Wigley; Carol M Black; Barri J Fessler; Peter A Merkel; Janet E Pope; Nadera J Sweiss; Mittie K Doyle; Bernhard Hellmich; Thomas A Medsger; Adele Morganti; Fabrice Kramer; Joseph H Korn; James R Seibold
Journal:  Ann Rheum Dis       Date:  2010-08-30       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.